What’s the current market cap for Astrana Health stock?

Astrana Health (ASTH) has a market cap of $1.9bn as of June 17, 2026.

What is the P/E ratio for Astrana Health stock?

The price to earnings (P/E) ratio for Astrana Health (ASTH) stock is 63.02 as of June 17, 2026.

Does Astrana Health stock pay dividends?

No, Astrana Health (ASTH) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Astrana Health dividend payment date?

Astrana Health (ASTH) stock does not pay dividends to its shareholders.

What is the beta indicator for Astrana Health?

Astrana Health (ASTH) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Astrana Health stock | $ASTH Share Price

13:30

15:10

16:45

18:25

20:00

About Astrana Health

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.

Ticker

$ASTH

Sector

Health

Primary listing

NASDAQ

Employees

3,000

Headquarters

Alhambra, United States

Website

www.astranahealth.com

Astrana Health Metrics

BasicAdvanced

$1.9bn

63.02

$0.61

0.94

What the Analysts think about Astrana Health

Analyst ratings (Buy, Hold, Sell) for Astrana Health stock.

Bulls say / Bears say

Fourth-quarter 2025 adjusted EPS of $0.54 topped consensus by $0.44, with revenue of $950.5 million, up 43% YoY, underscoring robust operational execution. (Reuters)

Full-year 2025 revenue reached $3.18 billion, up 56% YoY, while adjusted EBITDA grew 21% to $205.4 million and free cash flow of $104.5 million delivered record top-line and margin expansion. (Reuters)

Prospect Health integration is ahead of schedule, with retention and synergies tracking toward the high end of the $12–15 million annual target, underpinning confident guidance of ~24% revenue and ~29% EBITDA growth in 2026. (Reuters)

The company disclosed a material weakness in internal control over financial reporting related to acquisition and purchase accounting processes, delaying its 2025 Form 10-K and highlighting governance risks. (Reuters)

Barclays initiated coverage with an “equal-weight” rating, noting risks associated with the pending Prospect Health acquisition and potential integration challenges. (Reuters)

Shares trade at an elevated multiple of approximately 78 times forward earnings, suggesting richly valued equity relative to industry peers and limiting near-term upside. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Astrana Health Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Astrana Health Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ASTH

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Fourth-quarter 2025 adjusted EPS of $0.54 topped consensus by $0.44, with revenue of $950.5 million, up 43% YoY, underscoring robust operational execution. (Reuters)

Barclays initiated coverage with an “equal-weight” rating, noting risks associated with the pending Prospect Health acquisition and potential integration challenges. (Reuters)

Shares trade at an elevated multiple of approximately 78 times forward earnings, suggesting richly valued equity relative to industry peers and limiting near-term upside. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.